![Barry E. Toyonaga](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Barry E. Toyonaga
Career history of Barry E. Toyonaga
Former positions of Barry E. Toyonaga
Companies | Position | Start | End |
---|---|---|---|
Traversa Therapeutics, Inc.
![]() Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Corporate Officer/Principal | 05/08/2009 | 19/12/2012 |
Ventana Capital Management LLC
![]() Ventana Capital Management LLC Investment ManagersFinance Ventana Capital Management LLC (Ventana Capital) is a venture capital firm founded in 1984 by Tom O. Gephart. The firm is headquartered in Rancho Santa Margarita, California. | Private Equity Investor | - | 31/12/2008 |
JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
Protein Design Labs, Inc.
![]() Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Corporate Officer/Principal | - | - |
Training of Barry E. Toyonaga
University of Toronto | Doctorate Degree |
Statistics
International
United States | 5 |
Canada | 2 |
Operational
Corporate Officer/Principal | 3 |
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
JOHNSON & JOHNSON | Health Technology |
Private companies | 3 |
---|---|
Ventana Capital Management LLC
![]() Ventana Capital Management LLC Investment ManagersFinance Ventana Capital Management LLC (Ventana Capital) is a venture capital firm founded in 1984 by Tom O. Gephart. The firm is headquartered in Rancho Santa Margarita, California. | Finance |
Protein Design Labs, Inc.
![]() Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
Traversa Therapeutics, Inc.
![]() Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Commercial Services |
- Stock Market
- Insiders
- Barry E. Toyonaga
- Experience